 Paco Herson
Concepts (495)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 36 | 2025 | 338 | 9.970 |
Why?
| | Heart Arrest | 25 | 2025 | 339 | 5.390 |
Why?
| | TRPM Cation Channels | 12 | 2024 | 74 | 5.370 |
Why?
| | Hippocampus | 23 | 2025 | 895 | 3.430 |
Why?
| | Stroke | 22 | 2025 | 1120 | 3.390 |
Why?
| | Neuroprotective Agents | 16 | 2020 | 131 | 3.060 |
Why?
| | Neurons | 31 | 2023 | 1590 | 3.050 |
Why?
| | Cardiopulmonary Resuscitation | 16 | 2025 | 249 | 2.810 |
Why?
| | Sex Characteristics | 16 | 2024 | 762 | 2.320 |
Why?
| | Cell Death | 16 | 2021 | 374 | 2.080 |
Why?
| | Purkinje Cells | 7 | 2019 | 70 | 2.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 7 | 2024 | 188 | 1.800 |
Why?
| | Recovery of Function | 6 | 2025 | 653 | 1.760 |
Why?
| | Mice, Inbred C57BL | 48 | 2025 | 5757 | 1.610 |
Why?
| | CA1 Region, Hippocampal | 7 | 2024 | 52 | 1.590 |
Why?
| | Animals | 97 | 2025 | 36940 | 1.380 |
Why?
| | Gonadal Steroid Hormones | 5 | 2025 | 140 | 1.380 |
Why?
| | Androgens | 8 | 2014 | 187 | 1.340 |
Why?
| | Mice | 64 | 2025 | 17787 | 1.340 |
Why?
| | Long-Term Potentiation | 8 | 2025 | 198 | 1.220 |
Why?
| | Ischemia | 5 | 2022 | 409 | 1.190 |
Why?
| | Neuroprotection | 3 | 2020 | 42 | 1.150 |
Why?
| | Receptors, GABA-A | 5 | 2024 | 142 | 1.120 |
Why?
| | Disease Models, Animal | 24 | 2022 | 4295 | 1.100 |
Why?
| | Peptide Fragments | 2 | 2021 | 706 | 1.030 |
Why?
| | Signal Transduction | 11 | 2024 | 5079 | 1.000 |
Why?
| | Infarction, Middle Cerebral Artery | 12 | 2023 | 40 | 0.960 |
Why?
| | Poly(ADP-ribose) Polymerases | 4 | 2013 | 98 | 0.920 |
Why?
| | Reperfusion Injury | 8 | 2020 | 279 | 0.900 |
Why?
| | Hypothermia, Induced | 3 | 2016 | 80 | 0.900 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 5 | 2014 | 12 | 0.850 |
Why?
| | Male | 71 | 2025 | 67762 | 0.840 |
Why?
| | Calcium | 10 | 2022 | 1199 | 0.820 |
Why?
| | Brain Injuries, Traumatic | 4 | 2023 | 360 | 0.790 |
Why?
| | Brain | 13 | 2024 | 2668 | 0.770 |
Why?
| | Brain Injuries | 5 | 2021 | 494 | 0.750 |
Why?
| | Thrombosis | 3 | 2022 | 371 | 0.740 |
Why?
| | Patch-Clamp Techniques | 13 | 2019 | 286 | 0.710 |
Why?
| | Cognition | 3 | 2019 | 1153 | 0.690 |
Why?
| | Sex Factors | 11 | 2024 | 2071 | 0.680 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2016 | 124 | 0.680 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2020 | 219 | 0.660 |
Why?
| | Neuronal Plasticity | 8 | 2023 | 290 | 0.660 |
Why?
| | Cerebellum | 4 | 2011 | 224 | 0.650 |
Why?
| | Pregnanolone | 2 | 2011 | 37 | 0.630 |
Why?
| | Brain-Derived Neurotrophic Factor | 4 | 2019 | 131 | 0.630 |
Why?
| | Potassium Channels | 8 | 2003 | 151 | 0.630 |
Why?
| | Estradiol | 5 | 2018 | 521 | 0.620 |
Why?
| | Nogo Proteins | 1 | 2019 | 10 | 0.620 |
Why?
| | Neural Inhibition | 3 | 2024 | 169 | 0.570 |
Why?
| | Nerve Regeneration | 1 | 2018 | 59 | 0.560 |
Why?
| | Adult Stem Cells | 1 | 2018 | 40 | 0.560 |
Why?
| | Guideline Adherence | 1 | 2022 | 556 | 0.540 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 383 | 0.540 |
Why?
| | Long-Term Synaptic Depression | 2 | 2018 | 56 | 0.540 |
Why?
| | Estrogens | 5 | 2013 | 367 | 0.520 |
Why?
| | Nervous System Diseases | 1 | 2019 | 266 | 0.520 |
Why?
| | Cerebrovascular Disorders | 2 | 2024 | 96 | 0.510 |
Why?
| | Neurogenesis | 1 | 2018 | 149 | 0.510 |
Why?
| | Clotrimazole | 2 | 2013 | 3 | 0.500 |
Why?
| | Neural Stem Cells | 1 | 2018 | 156 | 0.500 |
Why?
| | Female | 44 | 2025 | 73304 | 0.500 |
Why?
| | Mice, Knockout | 11 | 2021 | 3015 | 0.500 |
Why?
| | Aging | 3 | 2019 | 1864 | 0.500 |
Why?
| | Sirtuin 2 | 1 | 2015 | 24 | 0.480 |
Why?
| | Microglia | 5 | 2018 | 251 | 0.480 |
Why?
| | Emergency Medical Services | 1 | 2022 | 552 | 0.480 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 500 | 0.470 |
Why?
| | Oxygen | 4 | 2012 | 931 | 0.460 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 434 | 0.450 |
Why?
| | Cell Culture Techniques | 3 | 2013 | 363 | 0.450 |
Why?
| | Tissue Plasminogen Activator | 3 | 2022 | 224 | 0.450 |
Why?
| | Cell Hypoxia | 4 | 2013 | 226 | 0.440 |
Why?
| | Animal Experimentation | 1 | 2014 | 6 | 0.430 |
Why?
| | Kynurenine | 2 | 2025 | 114 | 0.430 |
Why?
| | Naltrexone | 1 | 2015 | 97 | 0.430 |
Why?
| | Models, Animal | 2 | 2013 | 384 | 0.420 |
Why?
| | Inhibitory Postsynaptic Potentials | 2 | 2011 | 45 | 0.420 |
Why?
| | Rats | 18 | 2023 | 5647 | 0.410 |
Why?
| | Cerebral Cortex | 3 | 2021 | 433 | 0.400 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2003 | 50 | 0.400 |
Why?
| | Ion Channels | 4 | 2004 | 133 | 0.380 |
Why?
| | Peptides | 3 | 2023 | 985 | 0.370 |
Why?
| | Magnetic Fields | 3 | 2022 | 24 | 0.360 |
Why?
| | Synapses | 4 | 2021 | 427 | 0.340 |
Why?
| | Hydrogen Peroxide | 4 | 2020 | 328 | 0.330 |
Why?
| | Memory | 3 | 2023 | 248 | 0.330 |
Why?
| | Oxidative Stress | 7 | 2020 | 1317 | 0.330 |
Why?
| | Action Potentials | 7 | 2022 | 493 | 0.320 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2014 | 24 | 0.320 |
Why?
| | Progesterone | 3 | 2010 | 254 | 0.320 |
Why?
| | Dexmedetomidine | 3 | 2014 | 43 | 0.310 |
Why?
| | Age Factors | 5 | 2021 | 3295 | 0.310 |
Why?
| | Calcium Channels, T-Type | 2 | 2022 | 96 | 0.300 |
Why?
| | Rats, Sprague-Dawley | 9 | 2023 | 2486 | 0.300 |
Why?
| | Cells, Cultured | 10 | 2018 | 4193 | 0.300 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 365 | 0.290 |
Why?
| | Immunohistochemistry | 7 | 2016 | 1738 | 0.290 |
Why?
| | Glucose | 7 | 2014 | 1020 | 0.290 |
Why?
| | Ion Channel Gating | 6 | 2004 | 90 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1091 | 0.280 |
Why?
| | NAD | 2 | 1999 | 77 | 0.280 |
Why?
| | Sepsis | 3 | 2019 | 617 | 0.280 |
Why?
| | HEK293 Cells | 3 | 2020 | 730 | 0.270 |
Why?
| | Humans | 36 | 2025 | 137585 | 0.270 |
Why?
| | Memory Disorders | 2 | 2019 | 164 | 0.270 |
Why?
| | Time Factors | 12 | 2025 | 6828 | 0.260 |
Why?
| | Brain Infarction | 3 | 2016 | 23 | 0.260 |
Why?
| | Tryptophan | 2 | 2025 | 183 | 0.260 |
Why?
| | Colloids | 2 | 2017 | 60 | 0.250 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 2057 | 0.250 |
Why?
| | Dihydrotestosterone | 5 | 2013 | 44 | 0.240 |
Why?
| | Protective Agents | 2 | 2019 | 41 | 0.240 |
Why?
| | Military Personnel | 2 | 2023 | 544 | 0.230 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.220 |
Why?
| | Olfactory Receptor Neurons | 1 | 2004 | 41 | 0.210 |
Why?
| | Myelin Proteins | 3 | 2016 | 45 | 0.210 |
Why?
| | GABAergic Neurons | 1 | 2024 | 35 | 0.210 |
Why?
| | Epoxide Hydrolases | 2 | 2013 | 13 | 0.210 |
Why?
| | Oxidants | 2 | 2020 | 111 | 0.210 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 18 | 0.210 |
Why?
| | Calmodulin | 2 | 2019 | 76 | 0.210 |
Why?
| | Glycosaminoglycans | 1 | 2023 | 83 | 0.210 |
Why?
| | Smell | 1 | 2004 | 117 | 0.210 |
Why?
| | Spinocerebellar Degenerations | 1 | 2003 | 5 | 0.210 |
Why?
| | Potassium Channels, Calcium-Activated | 4 | 2004 | 11 | 0.210 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2023 | 29 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 2 | 2013 | 50 | 0.200 |
Why?
| | Orchiectomy | 3 | 2013 | 71 | 0.200 |
Why?
| | Corpus Striatum | 4 | 2016 | 167 | 0.200 |
Why?
| | Spinal Cord Ischemia | 2 | 2013 | 56 | 0.200 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2023 | 66 | 0.200 |
Why?
| | Pneumonia | 2 | 2021 | 639 | 0.200 |
Why?
| | Blood-Brain Barrier | 2 | 2022 | 138 | 0.200 |
Why?
| | Behavior, Animal | 3 | 2018 | 501 | 0.200 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 243 | 0.200 |
Why?
| | Spinal Cord | 3 | 2014 | 370 | 0.200 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 80 | 0.190 |
Why?
| | Cerebral Infarction | 1 | 2022 | 44 | 0.190 |
Why?
| | Primary Cell Culture | 2 | 2013 | 171 | 0.190 |
Why?
| | Heparitin Sulfate | 2 | 2019 | 50 | 0.190 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.190 |
Why?
| | Metabolomics | 2 | 2024 | 678 | 0.190 |
Why?
| | Myelin Sheath | 3 | 2023 | 167 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 313 | 0.190 |
Why?
| | Plasminogen | 1 | 2021 | 30 | 0.180 |
Why?
| | Information Systems | 1 | 2022 | 61 | 0.180 |
Why?
| | Phosphorylation | 4 | 2023 | 1759 | 0.180 |
Why?
| | Benzimidazoles | 2 | 2014 | 170 | 0.180 |
Why?
| | Receptors, Androgen | 3 | 2013 | 150 | 0.180 |
Why?
| | Spinal Cord Injuries | 2 | 2015 | 212 | 0.180 |
Why?
| | Organ Culture Techniques | 1 | 2021 | 156 | 0.180 |
Why?
| | Heroin | 1 | 2021 | 31 | 0.180 |
Why?
| | Blotting, Western | 5 | 2012 | 1226 | 0.180 |
Why?
| | Cell Survival | 6 | 2020 | 1120 | 0.180 |
Why?
| | Islets of Langerhans | 2 | 1997 | 803 | 0.180 |
Why?
| | Eclampsia | 1 | 2020 | 4 | 0.170 |
Why?
| | Encephalitis | 2 | 2014 | 136 | 0.170 |
Why?
| | Presynaptic Terminals | 1 | 2021 | 88 | 0.170 |
Why?
| | Metabolome | 1 | 2024 | 350 | 0.170 |
Why?
| | Insulinoma | 2 | 1997 | 26 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2017 | 198 | 0.170 |
Why?
| | Extinction, Psychological | 1 | 2021 | 86 | 0.170 |
Why?
| | Cell-Derived Microparticles | 1 | 2021 | 71 | 0.170 |
Why?
| | Amyloid beta-Peptides | 1 | 2023 | 220 | 0.170 |
Why?
| | Thalamus | 1 | 2021 | 107 | 0.160 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 553 | 0.160 |
Why?
| | Fibrinolysis | 2 | 2021 | 146 | 0.160 |
Why?
| | Death-Associated Protein Kinases | 1 | 2020 | 11 | 0.160 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2020 | 52 | 0.160 |
Why?
| | Cell Membrane | 2 | 2003 | 738 | 0.160 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 24 | 0.160 |
Why?
| | Inhibitory Concentration 50 | 1 | 2019 | 90 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 976 | 0.160 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 60 | 0.160 |
Why?
| | Intravital Microscopy | 1 | 2019 | 25 | 0.160 |
Why?
| | Insulin | 3 | 1999 | 2409 | 0.160 |
Why?
| | Optical Imaging | 1 | 2019 | 64 | 0.150 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2019 | 72 | 0.150 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 270 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 146 | 0.150 |
Why?
| | Models, Theoretical | 1 | 2023 | 578 | 0.150 |
Why?
| | Axons | 2 | 2018 | 198 | 0.150 |
Why?
| | Mutagenesis | 1 | 2019 | 179 | 0.150 |
Why?
| | Cofilin 1 | 1 | 2018 | 5 | 0.150 |
Why?
| | Mice, Transgenic | 6 | 2016 | 2167 | 0.150 |
Why?
| | Oligosaccharides | 1 | 2019 | 60 | 0.150 |
Why?
| | Drug Design | 1 | 2019 | 167 | 0.150 |
Why?
| | Calcineurin | 1 | 2019 | 108 | 0.150 |
Why?
| | Nerve Net | 1 | 2021 | 256 | 0.150 |
Why?
| | Protein Aggregation, Pathological | 1 | 2018 | 21 | 0.150 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.150 |
Why?
| | Thalamic Nuclei | 1 | 2018 | 10 | 0.140 |
Why?
| | Holoenzymes | 1 | 2018 | 24 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 692 | 0.140 |
Why?
| | Pre-Eclampsia | 1 | 2020 | 190 | 0.140 |
Why?
| | Interleukin-10 | 3 | 2015 | 302 | 0.140 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 213 | 0.140 |
Why?
| | Lateral Ventricles | 1 | 2018 | 35 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.140 |
Why?
| | Intracranial Arterial Diseases | 1 | 2017 | 8 | 0.140 |
Why?
| | Alloxan | 1 | 1997 | 4 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1164 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 261 | 0.140 |
Why?
| | Receptors, AMPA | 2 | 2018 | 141 | 0.130 |
Why?
| | Mitochondria | 2 | 2021 | 948 | 0.130 |
Why?
| | Receptors, Glutamate | 1 | 2016 | 25 | 0.130 |
Why?
| | Glutathione | 1 | 1999 | 356 | 0.130 |
Why?
| | Cerebral Arteries | 1 | 2017 | 59 | 0.130 |
Why?
| | Dementia | 1 | 2020 | 259 | 0.130 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 327 | 0.130 |
Why?
| | Leukoencephalopathies | 1 | 2016 | 19 | 0.130 |
Why?
| | Actins | 1 | 2018 | 416 | 0.130 |
Why?
| | Pericytes | 1 | 2016 | 34 | 0.120 |
Why?
| | Cations | 3 | 2003 | 84 | 0.120 |
Why?
| | Inflammation | 4 | 2021 | 2837 | 0.120 |
Why?
| | Spleen | 3 | 2015 | 514 | 0.120 |
Why?
| | Furans | 1 | 2015 | 24 | 0.120 |
Why?
| | Cell Communication | 2 | 2016 | 315 | 0.120 |
Why?
| | Collagen Type I | 1 | 2016 | 136 | 0.120 |
Why?
| | Tretinoin | 1 | 2016 | 123 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 346 | 0.120 |
Why?
| | Transfection | 2 | 2016 | 945 | 0.120 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 240 | 0.120 |
Why?
| | Brain Concussion | 1 | 2023 | 574 | 0.120 |
Why?
| | Arginase | 1 | 2015 | 32 | 0.120 |
Why?
| | Interleukin-1beta | 2 | 2014 | 372 | 0.120 |
Why?
| | Membrane Potentials | 5 | 1999 | 284 | 0.120 |
Why?
| | Calbindins | 1 | 2014 | 6 | 0.120 |
Why?
| | Neutrophil Activation | 1 | 2015 | 80 | 0.110 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.110 |
Why?
| | Dizocilpine Maleate | 1 | 2014 | 22 | 0.110 |
Why?
| | Calcium Channel Agonists | 1 | 2014 | 12 | 0.110 |
Why?
| | Trauma, Nervous System | 1 | 2014 | 2 | 0.110 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 78 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 2 | 2013 | 273 | 0.110 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2014 | 100 | 0.110 |
Why?
| | Microinjections | 2 | 2011 | 86 | 0.110 |
Why?
| | Quinolines | 1 | 2015 | 178 | 0.110 |
Why?
| | Aged | 6 | 2025 | 23961 | 0.110 |
Why?
| | Mutation | 2 | 2020 | 3958 | 0.110 |
Why?
| | Lentivirus | 2 | 2011 | 56 | 0.110 |
Why?
| | Nerve Tissue Proteins | 2 | 2016 | 596 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2015 | 119 | 0.110 |
Why?
| | Analysis of Variance | 3 | 2015 | 1316 | 0.110 |
Why?
| | Electroencephalography | 1 | 2016 | 423 | 0.110 |
Why?
| | CD40 Antigens | 1 | 2014 | 89 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1587 | 0.110 |
Why?
| | Cross Infection | 1 | 2016 | 256 | 0.100 |
Why?
| | Arachidonic Acids | 1 | 2013 | 62 | 0.100 |
Why?
| | Body Temperature | 1 | 2014 | 222 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 318 | 0.100 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 56 | 0.100 |
Why?
| | Embryo, Mammalian | 1 | 2013 | 232 | 0.100 |
Why?
| | Piperidines | 1 | 2014 | 206 | 0.100 |
Why?
| | Immune Tolerance | 1 | 2015 | 363 | 0.100 |
Why?
| | Glomerular Filtration Barrier | 1 | 2012 | 1 | 0.100 |
Why?
| | Ovariectomy | 3 | 2025 | 152 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 204 | 0.100 |
Why?
| | Polymerase Chain Reaction | 3 | 2012 | 1062 | 0.100 |
Why?
| | Testosterone | 3 | 2010 | 409 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 622 | 0.090 |
Why?
| | Endothelium | 1 | 2012 | 123 | 0.090 |
Why?
| | Microscopy, Immunoelectron | 1 | 2011 | 46 | 0.090 |
Why?
| | Iraq War, 2003-2011 | 2 | 2023 | 127 | 0.090 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2011 | 68 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2014 | 287 | 0.090 |
Why?
| | Afghan Campaign 2001- | 2 | 2023 | 132 | 0.090 |
Why?
| | Up-Regulation | 2 | 2025 | 843 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 165 | 0.090 |
Why?
| | Pyramidal Cells | 1 | 2011 | 74 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 10811 | 0.090 |
Why?
| | Biomarkers | 2 | 2025 | 4149 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2023 | 15657 | 0.080 |
Why?
| | United States | 3 | 2023 | 14841 | 0.080 |
Why?
| | Isoflurane | 1 | 2010 | 31 | 0.080 |
Why?
| | Anesthetics, Inhalation | 1 | 2010 | 35 | 0.080 |
Why?
| | Child | 4 | 2019 | 21935 | 0.080 |
Why?
| | Genetic Vectors | 1 | 2011 | 319 | 0.080 |
Why?
| | Cell Line | 5 | 2012 | 2847 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7635 | 0.080 |
Why?
| | Cell Movement | 1 | 2014 | 967 | 0.080 |
Why?
| | Ischemic Attack, Transient | 1 | 2010 | 65 | 0.080 |
Why?
| | Disease Progression | 1 | 2017 | 2757 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2018 | 2833 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 665 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1092 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1238 | 0.080 |
Why?
| | Motor Activity | 2 | 2011 | 718 | 0.080 |
Why?
| | Pregnancy | 3 | 2020 | 6763 | 0.070 |
Why?
| | Oligodendroglia | 2 | 2023 | 179 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 860 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2023 | 844 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 3457 | 0.070 |
Why?
| | Kidney | 2 | 2012 | 1468 | 0.070 |
Why?
| | Apoptosis | 3 | 2016 | 2553 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2011 | 718 | 0.060 |
Why?
| | Menopause | 1 | 2010 | 320 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 815 | 0.060 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 37 | 0.060 |
Why?
| | Muscle Denervation | 2 | 2002 | 9 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 408 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2011 | 847 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 955 | 0.060 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 1 | 2004 | 15 | 0.060 |
Why?
| | Electrophysiology | 3 | 2003 | 217 | 0.050 |
Why?
| | Decorin | 1 | 2023 | 7 | 0.050 |
Why?
| | Hospital Mortality | 2 | 2021 | 911 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 33479 | 0.050 |
Why?
| | Infarction | 1 | 2023 | 10 | 0.050 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 32 | 0.050 |
Why?
| | Cyclic AMP | 1 | 2004 | 234 | 0.050 |
Why?
| | Kv1.1 Potassium Channel | 1 | 2003 | 8 | 0.050 |
Why?
| | Genes, Lethal | 1 | 2003 | 30 | 0.050 |
Why?
| | Carbonic Anhydrases | 1 | 2003 | 14 | 0.050 |
Why?
| | Shal Potassium Channels | 1 | 2003 | 6 | 0.050 |
Why?
| | Acetazolamide | 1 | 2003 | 26 | 0.050 |
Why?
| | Fasciculation | 1 | 2002 | 2 | 0.050 |
Why?
| | Iraq | 1 | 2023 | 53 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2017 | 455 | 0.050 |
Why?
| | Databases, Factual | 2 | 2021 | 1357 | 0.050 |
Why?
| | Afghanistan | 1 | 2023 | 71 | 0.050 |
Why?
| | Spatial Memory | 1 | 2022 | 26 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10388 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 153 | 0.050 |
Why?
| | Models, Neurological | 1 | 2004 | 242 | 0.050 |
Why?
| | Tolbutamide | 2 | 1999 | 4 | 0.050 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2021 | 9 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 452 | 0.050 |
Why?
| | Muscular Diseases | 1 | 2002 | 114 | 0.050 |
Why?
| | Muscle, Skeletal | 2 | 2002 | 1724 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2014 | 437 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2011 | 51 | 0.040 |
Why?
| | Self Administration | 1 | 2021 | 123 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2023 | 200 | 0.040 |
Why?
| | Aorta, Thoracic | 2 | 2013 | 267 | 0.040 |
Why?
| | Adoptive Transfer | 2 | 2011 | 219 | 0.040 |
Why?
| | Synaptic Transmission | 1 | 2003 | 289 | 0.040 |
Why?
| | Tumor Necrosis Factors | 1 | 2020 | 11 | 0.040 |
Why?
| | Swine | 1 | 2023 | 775 | 0.040 |
Why?
| | Inflammation Mediators | 2 | 2013 | 513 | 0.040 |
Why?
| | Neurotoxins | 1 | 2020 | 29 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2001 | 218 | 0.040 |
Why?
| | Nucleus Accumbens | 1 | 2021 | 138 | 0.040 |
Why?
| | Air Ambulances | 1 | 2020 | 32 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2003 | 443 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2020 | 239 | 0.040 |
Why?
| | Dendritic Spines | 1 | 2020 | 65 | 0.040 |
Why?
| | Thapsigargin | 1 | 1999 | 20 | 0.040 |
Why?
| | Cesium | 1 | 1999 | 20 | 0.040 |
Why?
| | Ion Transport | 1 | 1999 | 60 | 0.040 |
Why?
| | Lymph Nodes | 2 | 2011 | 491 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1250 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1060 | 0.040 |
Why?
| | Barium | 1 | 1997 | 26 | 0.040 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2018 | 20 | 0.040 |
Why?
| | Glutamic Acid | 1 | 2020 | 246 | 0.030 |
Why?
| | Resuscitation | 1 | 2020 | 251 | 0.030 |
Why?
| | Thiourea | 1 | 1997 | 40 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 249 | 0.030 |
Why?
| | Magnesium | 1 | 1997 | 156 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 1997 | 88 | 0.030 |
Why?
| | Seizures | 1 | 2020 | 426 | 0.030 |
Why?
| | Kinetics | 2 | 1997 | 1670 | 0.030 |
Why?
| | Oligopeptides | 1 | 1999 | 271 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2018 | 283 | 0.030 |
Why?
| | Exons | 1 | 2018 | 355 | 0.030 |
Why?
| | Niacinamide | 1 | 1997 | 82 | 0.030 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2016 | 47 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 404 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 500 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 445 | 0.030 |
Why?
| | Protein Domains | 1 | 2018 | 289 | 0.030 |
Why?
| | Heme Oxygenase-1 | 1 | 2016 | 64 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 119 | 0.030 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 50 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2016 | 106 | 0.030 |
Why?
| | Hypoxia | 2 | 2014 | 1112 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 418 | 0.030 |
Why?
| | Cell Polarity | 1 | 1997 | 141 | 0.030 |
Why?
| | Stromal Cells | 1 | 2016 | 112 | 0.030 |
Why?
| | Cytokines | 2 | 2014 | 2085 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 785 | 0.030 |
Why?
| | Cysteine | 1 | 1997 | 204 | 0.030 |
Why?
| | Adult | 2 | 2021 | 37929 | 0.030 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 145 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 223 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2012 | 436 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 21513 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 179 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 1997 | 491 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2015 | 110 | 0.030 |
Why?
| | California | 1 | 2016 | 431 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 187 | 0.030 |
Why?
| | Nanostructures | 1 | 2016 | 107 | 0.030 |
Why?
| | Hindlimb | 1 | 2015 | 128 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4565 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1996 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1793 | 0.030 |
Why?
| | Locomotion | 1 | 2015 | 106 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 184 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 1997 | 622 | 0.030 |
Why?
| | Hematoxylin | 1 | 2013 | 6 | 0.030 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2013 | 10 | 0.030 |
Why?
| | Fluoresceins | 1 | 2013 | 47 | 0.030 |
Why?
| | Constriction | 1 | 2013 | 47 | 0.030 |
Why?
| | Chalcones | 1 | 2013 | 7 | 0.030 |
Why?
| | CREB-Binding Protein | 1 | 2013 | 31 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5742 | 0.030 |
Why?
| | Movement | 1 | 2016 | 278 | 0.030 |
Why?
| | Arginine | 1 | 2015 | 271 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2607 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2224 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.030 |
Why?
| | Ligation | 1 | 2013 | 92 | 0.030 |
Why?
| | Apamin | 2 | 2004 | 4 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 269 | 0.030 |
Why?
| | Hypoglycemic Agents | 2 | 1999 | 1291 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1509 | 0.020 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 35 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 233 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2031 | 0.020 |
Why?
| | Fibronectins | 1 | 2012 | 133 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2012 | 119 | 0.020 |
Why?
| | Proteins | 1 | 1997 | 1009 | 0.020 |
Why?
| | Lymphocyte Subsets | 1 | 2011 | 87 | 0.020 |
Why?
| | Receptors, CCR7 | 1 | 2011 | 32 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1622 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 56 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2011 | 102 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 367 | 0.020 |
Why?
| | Blood | 1 | 2011 | 107 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2010 | 90 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 321 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2011 | 416 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 431 | 0.020 |
Why?
| | Aromatase | 1 | 2010 | 32 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2010 | 26 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2475 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2010 | 54 | 0.020 |
Why?
| | Aromatase Inhibitors | 1 | 2010 | 54 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2010 | 67 | 0.020 |
Why?
| | Renal Circulation | 1 | 2010 | 58 | 0.020 |
Why?
| | Lipocalins | 1 | 2010 | 36 | 0.020 |
Why?
| | Estrogen Receptor beta | 1 | 2010 | 40 | 0.020 |
Why?
| | Exploratory Behavior | 1 | 2010 | 92 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2010 | 59 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 886 | 0.020 |
Why?
| | Lipocalin-2 | 1 | 2010 | 79 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 496 | 0.020 |
Why?
| | Castration | 1 | 2009 | 14 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 99 | 0.020 |
Why?
| | Androgen Receptor Antagonists | 1 | 2009 | 34 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 210 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2009 | 82 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1242 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.020 |
Why?
| | Creatinine | 1 | 2010 | 499 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 331 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1178 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.020 |
Why?
| | Autoimmunity | 1 | 2011 | 908 | 0.010 |
Why?
| | Pediatrics | 1 | 2013 | 1101 | 0.010 |
Why?
| | Infant | 1 | 2018 | 9465 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13209 | 0.010 |
Why?
| | Child, Preschool | 1 | 2018 | 11074 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 316 | 0.010 |
Why?
| | Evoked Potentials | 1 | 2004 | 123 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 188 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 84 | 0.010 |
Why?
| | Blood Pressure | 1 | 2010 | 1786 | 0.010 |
Why?
| | Myoblasts | 1 | 2003 | 84 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2003 | 269 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2001 | 40 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2001 | 46 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2003 | 190 | 0.010 |
Why?
| | Cobalt | 1 | 2001 | 52 | 0.010 |
Why?
| | Chelating Agents | 1 | 2001 | 75 | 0.010 |
Why?
| | Potassium | 1 | 2001 | 147 | 0.010 |
Why?
| | Calcium Channels | 1 | 2001 | 159 | 0.010 |
Why?
| | Electromyography | 1 | 2002 | 400 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2002 | 424 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2181 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2900 | 0.010 |
Why?
| | Biotransformation | 1 | 1997 | 65 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1457 | 0.010 |
Why?
| | Potassium Channel Blockers | 1 | 1996 | 37 | 0.010 |
Why?
| | Leptin | 1 | 1997 | 236 | 0.010 |
Why?
| | Xenopus laevis | 1 | 1996 | 106 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 345 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 1996 | 229 | 0.010 |
Why?
| | Oocytes | 1 | 1996 | 181 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 515 | 0.010 |
Why?
|
|
Herson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|